Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow research hub

A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (MERCUTIO)

This study is looking at a new medicine, MYK-224, for people with a heart condition called hypertrophic cardiomyopathy. It aims to see if the medicine is safe, how it works in the body, and if it helps improve heart function and symptoms.